AstraZeneca PLC (AZN) has a MoatMap StockRank of 73/100 based on Quality (66/100), Value (30/100), and Momentum (57/100) factor scores. The current signal is BUY. AstraZeneca is a premier global pharmaceutical company poised to benefit from the 'Sticky Rates & Defensive Strength' macro theme. In an environment of elevated inflation and persistent geopolitical uncertainty, its essential healthcare products, robust drug pipeline, and pricing power provide a stable, defensive earnings stream. The market may be underestimating the sustained re-rating potential for quality defensives like AZN as capital reallocates from speculative growth into resilient compounders with strong moats and reliable free cash flow generation. Its un-copyable intellectual property, high ROIC, and long reinvestment runway align perfectly with the 'Durable Compounders at GARP' philosophy, offering an asymmetric risk-reward profile in a challenging macro backdrop.
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines in oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The company boasts a robust pipeline of innovative therapies, strong R&D capabilities, and global market presence, making it a leader in multiple therapeutic areas. Its commitment to breakthrough science provides a significant competitive moat in the healthcare industry.
| Price | $181.58 |
| Market Cap | $281.2B |
| P/E (TTM) | 27.39 |
| P/E (Forward) | 30.81 |
| Price/Book | 5.95 |
| Return on Equity | 23.5% |
| Return on Invested Capital | 16.8% |
| Debt/Equity | 71.81 |
| Gross Margin | 81.5% |
| Operating Margin | 28.2% |
| Revenue Growth | 12.5% |
| Dividend Yield | 1.7% |
| Free Cash Flow | $6.5B |
AstraZeneca PLC operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United Kingdom).